By Product Type :

The product type segment is categorized into chemiluminescent immunoassay (CLIA), enzyme linked immunosorbent assay (ELISA), fluorescence immunoassay analyser (FIA), and others. In 2022, the chemiluminescent immunoassay (CLIA) segment accounted for the highest market share in the clinical immunoanalyzer market. Chemiluminescence immunoassay is a vital assay that amalgamates the chemiluminescence technique in combination with immunochemical reactions. The primary benefit of chemiluminescent immunoassays is the simplicity of the detector to record data. Additionally, chemiluminescent immunoassays emit light, which eliminates the need for excitation from a light source or a detector for a diverse range of wavelengths not in the visible spectrum. Hence, chemiluminescent immunoassays are ideal for application in diagnostic labs, hospitals, and many more. Thus, the above benefits associated with chemiluminescence immunoassay are amplifying the adoption of the product in hospitals, clinics, and others to ensure superior accuracy in the samples. This, in turn, is supplementing the market growth.

However, the enzyme linked immunosorbent assay (ELISA) segment is projected to be the fastest-growing segment during the forecast period. This is due to the increasing development of a new range of enzyme linked immunosorbent assay, which is fostering segmental growth. For instance, in March 2022, Promega Corporation, a healthcare manufacturer in the United States introduced Lumit Immunoassays for enzyme linked immunosorbent assay users.

By End User :

The end user segment is categorized into hospitals, diagnostic labs, clinics, and others. In 2022, hospitals segment accounted for the highest market share of 38.48% in the overall clinical immunoanalyzer market. The clinical immunoanalyzer is equipped with prominent features such as maximum system uptime, improved reliability, intuitive interfaces, easy-to-use features, minimized training requirements, streamlined inventory, and management tasks. As a result, clinical immunoanalyzer is frequently employed in hospitals to ensure superior reliability, excellent scalability, and simple processing. For instance, in 2022, various hospital construction projects commenced at the global level, including USD 538 million Gainesville Hospital Expansion project in the United States (project completion year 2030), USD 800 million Techo Santepheap Phnom Penh Covid-19 Treatment Center project in Cambodia (project completion year 2030), USD 1,760 million Lok Ma Chau Emergency Hospital Development in China (project completion year Q4 2023), among others. Thus, the development of new hospitals will accelerate the demand for clinical immunoanalyzer to enable superior simplification in sampling. This factor will create a potential for market growth.

However, the clinics segment is expected to be the fastest-growing segment during the forecast period. This growth is attributed to factors such as increasing investment in new clinics, government initiatives for public clinics, and others.

Get More Information

Download Sample Report

By Region :

The regional segment includes North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

In 2022, North America accounted for the highest market share at 39.08% and was valued at USD 1,872.76 million, and is expected to reach USD 2,765.39 million in 2030. In North America, the U.S. accounted for the highest market share of 69.65% during the base year of 2022. The increasing demand for rapid sampling, accurate examination of protein, and others are some of the prominent factors driving the development of new clinical immunoanalyzer in the North America region. For instance, in July 2023, Fapon Biopharma, a United States-based player dealing in the chemiluminescent immunoassay product range unveiled a new range of chemiluminescence immunoassay systems named Shine i8000/9000. The Shine i8000/9000 is equipped with a fully automated analyzer and superior speed with an ultra-high throughput of 900 tests per hour. Likewise, the product empowers its partners to construct premium clinical diagnostic solutions. Therefore, the introduction of a new range of clinical immunoanalyzer in North America is benefiting the market growth in the region.

Furthermore, Asia Pacific is expected to witness significant growth over the forecast period, growing at a CAGR of 5.7% during 2023-20230. This is due to the exponential growth in the adoption of clinical immunoanalyzer by end users such as hospitals, diagnostic labs, and clinics, among others.